WebJun 15, 2024 · Obalon will issue 10.4 million shares to acquire ReShape at an exchange ratio of 1.6911 Obalon Shares for each share of ReShape Common Stock. Immediately … WebMay 24, 2024 · DGAP-News: ReShape Lifesciences Inc. / Key word(s): Miscellaneous Reminder: Obalon Therapeutics, Inc. Urges Stockholders to IMMEDIATELY Vote FOR All Proposals Related to the Merger with ReShape Lifesciences Inc 2024-05-24 / 13:35 The issuer is solely responsible for the content of this announcement.
SEC Filings ReShape Lifesciences
WebApr 11, 2024 · ReShape Lifesciences® is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and ... WebJan 20, 2024 · (RTTNews) - Shares of Obalon Therapeutics Inc. (OBLN) surged over 75% on Wednesday morning on the news that the company will merger with ReShape … telus 5g
ReShape Lifesciences Transformative Devices for Obesity …
WebApr 11, 2024 · SAN CLEMENTE, Calif., April 11, 2024 (GLOBE NEWSWIRE) — ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/792,094, … WebOrbera vs Reshape: While Reshape is a slightly newer device, both gastric balloons were recently approved by the FDA in 2015. The Orbera single sphere is filled with 550 cc of saline, while the Reshape double balloon is filled with 900 cc. With Reshape, an obesity-related comorbidity is required. telus 7b1